

As of: March 2025

FACT SHEET

COMPANY PROFILE

STRATEC SE (Frankfurt: SBS; Prime Standard, SDAX, ISIN: DE000STRA555) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. Furthermore, the company offers integrated laboratory software and complex consumables for diagnostic and medical applications. STRATEC covers the entire value chain - from development to design and production through to quality assurance.

The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of its own patented technologies.

MANAGEMENT BOARD



Marcus Wolfinger



Dr. Claus Vielsack



Dr. Georg Bauer

SUPERVISORY BOARD

- Prof. Dr. Georg Heni
- Dr. Frank Hiller
- Dr. Rolf Vornhagen
- Dr. Patricia Geller

STOCK FUNDAMENTALS

ISIN	DE000STRA555
WKN	STRA55
Symbol	SBS
Reuters Code	SBSG.DE
Branch	Pharma & Healthcare
Transparency level	Prime Standard
Market segment	Regulated Market
Type of shares	Registered Shares
Registered capital	12,157,841 Euro
No. of shares	12.157.841
Initial listing	Aug 25, 1998
Stock exchanges	Xetra; Frankfurt am Main and other regional exchanges in Germany

SHAREHOLDER STRUCTURE

Investor group	Share
Fixed and family ownership (incl. investment companies)	40.36%
Treasury shares	0.02%
Free float	59.62%
Total	100.00%

STOCK CHART



FACT SHEET

KEY FIGURES AT A GLANCE

IFRS (in € million)	2023	2022	2021	2020	2019
Sales	261.9	274.6	287.3	250.1	214.2
Adjusted EBIT ¹	27.1	45.1	54.3	41.7	29.3
Adjusted EBIT margin (%) ¹	10.3	16.4	18.9	16.7	13.7
Adjusted consolidated net income ¹	16.7	34.7	45.1	35.2	24.1
Adjusted earnings per share (€) ¹	1.37	2.86	3.73	2.92	2.01
Dividend per share (€)	0.55	0.97	0.95	0.90	0.84
No. of employees	1,522	1,481	1,398	1,319	1,302
Total assets	466.6	397.5	368.5	331.9	299.4
Equity ratio (%)	50.0	56.6	55.8	52.2	53.1

¹ For comparison purposes, adjusted figures for 2023 have been adjusted to exclude amortization from purchase price allocations in the context of acquisitions, as well as for other one-off items (consulting and reorganization expenses in connection with M&A activities and one-off personnel expenses). In the previous year, earnings figures were additionally adjusted to exclude a provision for expected back payments of tax (including interest payments).

CONFERENCES

Apr 03, 2025	METZLER Small Cap Days Organized by: Metzler Capital Markets
May 13, 2025	Pan European Small and Mid-Cap Conference Organized by: UBS
May 14, 2025	Berenberg Diagnostics Conference Organized by: Berenberg Bank
May 20, 2025	Berenberg European Conference Organized by: Berenberg Bank
Jun 11, 2025	Warburg Highlights Conference Organized by: Warburg Research
Sep 03-04, 2025	22nd Annual Goldman Sachs European Medtech and Healthcare Conference Organized by: Goldman Sachs
Sep 23, 2025	14th German Corporate Conference Organized by: Berenberg & Goldman Sachs
Nov 25, 2025	German Equity Forum Organized by: Deutsche Börse - Analysts' Conference -
Nov 26, 2025	Digital Diagnostics Day Organized by: Kepler Cheuvreux

FINANCIAL CALENDAR

Mar 27, 2025	Publication Annual Report 2024
May 09, 2025	Publication Quarterly Statement Q1 2025
May 23, 2025	Annual General Meeting
Aug 19, 2025	Publication Half-Year Financial Report H1 2025
Nov 07, 2025	Publication Quarterly Statement 9M 2025

CONTACT

STRATEC SE
Gewerbestr. 37
75217 Birkenfeld
Germany

☎ +49 7082 7916-0
🌐 www.strattec.com

Investor Relations
☎ +49 7082 7916-991
✉ ir@strattec.com